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Background: Endobronchial ultrasound-guided transbronchial 
needle aspiration (EBUS-TBNA) enables minimally invasive lymph 
node sampling during bronchoscopy under conscious sedation. The 
primary purpose of this study was to investigate the safety profile of 
EBUS-TBNA in an elderly population. The secondary aim was to 
assess the efficacy of EBUS-TBNA for nodal staging and pathologi-
cal diagnosis in elderly patients with primary lung cancer.
Methods: This was a prospective cohort study of patients undergo-
ing EBUS-TBNA, between March 2010 and August 2012, at a single 
U.K. hospital site. Procedure and outcome data including 6-month 
 follow-up were collected prospectively. Patients were divided into less 
than 70 (<70yrs) or 70 and older (≥70yrs) age categories for analysis.
Results: Four hundred and fifty-one patients underwent  EBUS-TBNA 
during the study period. Mean age of the patients was 66.9 ± 11.9 
years, 43.9% (n=198) of them were aged ≥70yrs. Older patients 
(≥70yrs) had a worse performance status (p=0.0001) and required 
significantly lower levels of sedation (p<0.000001) but had similar 
overall complication rates (<70yrs 8.7% versus ≥70yrs 5.1%; p=0.13) 
and tolerated the procedure better than younger patients (p=0.036). 
Sensitivity (92.9% versus 86.4%; p=0.12) was equivalent, but nega-
tive predictive value (91.8% versus 73.9%; p=0.001) and diagnos-
tic accuracy (96.0% versus 90.2%; p=0.02) of nodal sampling in 
patients with confirmed or suspected lung cancer (n=273) was higher 
in the ≥70yrs cohort (n=131, 48.0%). However, the prevalence of 
nodal malignancy was significantly different between the two groups 
as was the proportion of patients subject to surgical lymph node sam-
pling after negative EBUS-TBNA. EBUS-TBNA samples produced 
low non–small-cell lung cancer–not otherwise specified rates (6.9%) 
and high levels of successful epidermal growth factor receptor muta-
tion analysis (97.5%) irrespective of age category.
Conclusion: EBUS is a safe and well-tolerated procedure in elderly 
patients, which facilitates accurate pathological diagnosis and mini-
mally invasive staging in patients with lung cancer.
Key Words: Bronchoscopy, Endobronchial ultrasound, Geriatric 
oncology, Non–small-cell lung cancer.
(J Thorac Oncol. 2014;9: 370–376)
The incidence of lung cancer increases with age, with a median age of 70 years at diagnosis.1 Prognosis is deter-
mined by a variety of tumor- and patient-related characteristics, 
which include stage, performance status, and comorbidities. 
Chronological age has been associated with prognosis2 but 
not consistently.3,4 Evidence suggests that there are consider-
able health inequalities in relation to age, involving all aspects 
of the patient journey from diagnosis to treatment. Data from 
a large U.K. study revealed that patients over the age of 70 
years had a reduced likelihood of receiving both a histological 
diagnosis and cancer treatment despite adjustments for stage, 
performance status, and comorbidity.5
Accurate staging is central to providing the most appro-
priate lung cancer treatment. Results from two recent large 
population-based studies (136,993 and 26,243 patients, 
respectively) have both shown that 52% of lung cancer 
patients in the United Kingdom are recorded as stage one 
to three at the time of diagnosis.6,7 In other words, the most 
appropriate lung cancer treatment is dependent on nodal stag-
ing in over half of all patients. Noninvasive nodal staging has 
limitations; for example, a meta-analysis of both computed 
tomography (CT; sensitivity 51%) and positron emission 
tomography (PET) scan (sensitivity 75%) showed relatively 
low sensitivity for the detection of nodal metastases,8 under-
lining the importance of pathological nodal staging. Until 
recent years this required mediastinoscopy under general 
anesthesia, potentially limiting its use in the comorbid elderly. 
Endobronchial ultrasound-guided transbronchial needle aspi-
ration  (EBUS-TBNA) allows identification and sampling of 
mediastinal and hilar lymph nodes as well as of tumor masses 
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lying adjacent to the central airways under conscious seda-
tion. The primary aim of this study was to examine the safety 
of EBUS-TBNA in elderly patients. The secondary aim was 
to assess the efficacy of EBUS-TBNA for nodal staging and 
pathological diagnosis in elderly patients with confirmed or 
suspected primary lung cancer.
PATIENTS AND METHODS
We conducted a prospective observational cohort study 
of patients who underwent EBUS-TBNA in the bronchoscopy 
unit at the University Hospital of South Manchester from March 
2010 to August 2012. University Hospital of South Manchester 
provides a tertiary EBUS-TBNA service for a large cancer net-
work consisting of 11 other National Health Service Trusts. 
Referral indications for EBUS-TBNA include: nodal staging 
in suspected or confirmed primary lung cancer, pathological 
confirmation in suspected advanced lung cancer where nodal 
staging is not required, isolated mediastinal lymphadenopathy, 
lymphadenopathy in the context of an extrapulmonary cancer, 
and pathological diagnosis of a central intrapulmonary lesion 
deemed accessible with EBUS-TBNA (if both intrapulmonary 
sampling and nodal staging are required in the same procedure 
the indication is classified as nodal staging).
All patients who underwent EBUS-TBNA during this 
time period were included. Ethical approval for the study 
was not required as the intervention and data collection form 
part of our standard clinical care. Procedures were performed 
under conscious sedation, without anesthetic support, using 
incremental doses of alfentanyl and midazolam. A total of five 
operators performed all procedures: two lung cancer physi-
cians, a nurse consultant bronchoscopist, and two consecu-
tive interventional bronchoscopy fellows. Two operators were 
present for all procedures; the primary operator performed the 
bronchoscopy and the secondary operator was responsible for 
sampling. Standard diagnostic bronchoscopy was performed 
before all EBUS procedures by using Olympus (BFF260 or 
BF6C260; South-on-se, Essex, United Kingdom) broncho-
scopes. EBUS-TBNA was performed using an Olympus 
BF-UC260FW ultrasonic bronchoscope and either 21G or 
22G needles. In patients requiring nodal staging for primary 
lung cancer a systematic examination of the mediastinum was 
performed and all lymph nodes that met any of the follow-
ing criteria were sampled: more than 10 mm short axis on CT, 
abnormal nodal fluorodeoxyglucose avidity above that of the 
mediastinal blood pool on PET-CT or abnormal ultrasound 
appearances (defined according to the endobronchial ultra-
sound image classification system proposed by Fujiwara et al.9: 
heterogenous echogenicity, round shape, distinct margins, or 
the presence of a coagulation necrosis sign). N3 nodes were 
sampled before N2 nodes, followed by N1 nodes. Sampling 
of lymph nodes from the esophagus was not performed. In 
those patients undergoing EBUS-TBNA for other indications 
a targeted procedure was performed based on preprocedure 
radiology without a systematic mediastinal evaluation.
The data collected prospectively included patient char-
acteristics, procedural and outcome-related information. 
Complications were recorded by the primary operator after 
the procedure, following patient recovery. Complications 
were categorized as major or minor based on U.K. national 
guidelines.10 Major complications included: major bleeding 
(defined as the need for resuscitation, transfusion, critical 
care admission, or death), cardiac arrhythmia requiring inter-
vention, seizure, myocardial infarction or pulmonary edema, 
pneumothorax requiring intercostals chest drain or aspiration, 
oversedation requiring ventilatory support or sedation rever-
sal, unplanned hospital admission, or death. Minor complica-
tions included: mild or moderate bleeding (defined as the need 
for continual suctioning or vasoconstrictors), cardiac arrhyth-
mia not requiring intervention, hypotension requiring inter-
vention, and poor tolerance of the procedure requiring early 
termination). EBUS-TBNA sampling was only classified as a 
true negative if surgical sampling and/or 6 months of follow-
up did not demonstrate evidence of malignancy. EBUS-TBNA 
samples were examined by a specialist thoracic pathologist 
and classified according to standard pathological criteria 
using both morphology and immunohistochemistry. Samples 
deemed inadequate by the reporting pathologist were classi-
fied as a negative EBUS-TBNA and subsequently categorized 
into “true-negative” or “false-negative” based on subsequent 
sampling and/or 6 months of clinical–radiological follow-up.
Patients were divided into less than 70 (<70yrs) or 70 
and older (≥70yrs) age categories for analysis. The primary 
outcome measure was procedure safety and we postulated that 
the risks for elderly patients with confirmed or suspected lung 
cancer undergoing EBUS-TBNA would be the same for elderly 
people undergoing EBUS-TBNA for all other indications. For 
this reason, all patients regardless of indication were included in 
the safety analysis. Secondary outcome measures were proce-
dure efficacy in nodal staging and pathological confirmation in 
advanced disease. Efficacy analysis was therefore restricted to 
patients undergoing EBUS-TBNA for these specific indications. 
Data were analyzed using SPSS (version 20.0.0). Categorical 
data are presented as frequencies and χ2 tests used to determine 
significance. Continuous data are presented as mean values 
with standard deviations and t tests used to detect differences. 
We estimated a complication rate in this study of 10% based on 
two prospective studies of standard flexible bronchoscopy11,12; 
a sample size of 440 (assuming 20% higher recruitment in 
patients below the age of 70) has 80% power to detect a 10% 
difference in complication rate between the groups at a 0.05 
two-sided significance level (STATA version 10.1).
RESULTS
Patient and Procedure Characteristics
Four hundred and fifty-one patients underwent 
 EBUS-TBNA, over half were men (242 of 451, 53.7%) and 
mean age was 66.9 ± 11.9 years (range, 20–93 years). Two 
hundred and fifty-three patients were less than 70yrs (56.1%) 
and 198 (43.9%) were 70yrs or older. Fifty-six patients were 
aged over 80 yrs. There was no significant difference in 
sex (p=0.30). Performance status was significantly lower in 
patients who were 70yrs or older (p=0.0001). Nodal staging 
was a more common indication in the 70yrs and  older-age 
category (131 of 198, 66.2% versus 142 of 253, 56.1%, 
p=0.03), whereas significantly more patients aged less than 
70yrs underwent EBUS-TBNA for investigation of isolated 
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mediastinal/hilar lymphadenopathy (51 of 253, 20.2% versus 
19 of 198, 9.6%, p=0.002; Table 1). The final diagnosis was 
primary lung cancer in 328 patients (173, 68.4% in <70yrs 
and 155, 78.3% in ≥70yrs; p=0.02), extrathoracic malignancy 
in 32 patients (17, 6.7% in <70yrs and 15, 7.6% in ≥70yrs), 
and benign disease in 91 patients (63, 24.9% in <70yrs and 28, 
14.1% in ≥70yrs; p=0.005).
Safety Profile
Mean doses of sedation were lower in the 70yrs and 
older category but the duration of procedure did not differ 
(Table 1). Overall, 32 complications were recorded (7.1% of 
all procedures). Two (0.4%) were classified as major compli-
cations and 30 (6.7%) as minor complications. Both major 
complications occurred in the 70yrs and older category. The 
two major complications consisted of: (1) an approximately 
50 ml of self-limiting hemoptysis after EBUS-TBNA lead-
ing to overnight admission for observation (defined as major 
complication because of unplanned hospital admission rather 
than bleeding) and (2) persistent postprocedure hypoxia with 
reduced respiratory effort requiring sedation reversal leading 
to resolution of symptoms and full recovery. There was no 
significant difference in the rate of minor (p=0.057) or major 
(p=0.19) complications between age groups, though poor pro-
cedural tolerance was significantly more common in the less 
than 70yrs age group (p=0.036) despite the higher levels of 
sedation. No complications (major or minor) were recorded in 
the 56 patients aged over 80 years. There was no statistically 
significant difference in complication rate between the two 
age cohorts according to indication for EBUS or performance 
status (Table 2).
Efficacy of EBUS-TBNA in Lung Cancer Staging
A total of 273 patients underwent EBUS-TBNA for 
nodal staging of suspected or confirmed primary lung cancer 
(n=142, 52.0% <70yrs and n=131, 48.0% ≥70yrs). On the basis 
of the pre-EBUS staging CT scan early nodal stage (clinical 
stage N0/1) was significantly more frequent, compared with 
TABLE 1.  Comparison of Sex, Performance Status, Sedation Dose, Duration of Procedure, and Complications Stratified by Age 
Group
Measure
Age Category (yrs)
p Value<70 ≥70
Number of patients 253 198 -
Sex: M/F (%M) 130/123 (51.4) 112/86 (56.6) 0.30
Performance status n (%) 0 95 (37.5) 16 (8.1) 0.0001
1 115 (45.5) 93 (47.0)
2 32 (12.6) 77 (38.9)
3 11 (4.4) 12 (6.0)
Lung function mean ±SD FEV
1
 (L) 1.9 ± 0.8 1.7 ± 0.6 0.09
FEV1 predicted (%) 70.7 ± 27.3 80.8 ± 34.2 0.22
DLCO predicted (%) 66.0 ± 15.8 63.3 ± 18.9 0.59
Indication for EBUS-TBNA Nodal staginga 142 (56.1) 131 (66.2) 0.03
Advanced stageb 26 (10.3) 25 (12.6) 0.43
Isolated LNsc 51 (20.2) 19 (9.6) 0.002
Extrapulmonary Cad 14 (5.5) 8 (4.0) 0.47
Intrapulmonary masse 20 (7.9) 15 (7.6) 0.90
Sedation Midazolam [mg] 3.4 ± 1.2 2.6 ± 1.0 < 0.000001
Alfentanyl [mcg] 531 ± 214 394 ± 187 < 0.000001
Procedure duration [min]f 39.4 ± 10.0 37.0 ± 11.5 0.17
Complications n (%) All 22 (8.7) 10 (5.1) 0.13
Major: all 0 2 (1.0) 0.19
Minor: all 22 (8.7) 8 (4.0) 0.057
Classification of minor 
complications n (%)
Poor tolerance/
Early termination
16 (6.3) 4 (2.0) 0.036
Minor bleeding 4 (1.6) 3 (1.5) 1.00
Transient hypotension 2 (0.8) 1 (0.5) 1.00
aNodal staging = suspected or pathologically confirmed primary lung cancer requiring nodal staging to define management.
bAdvanced stage = suspected advanced stage lung cancer where only pathological confirmation required without formal nodal staging. 
cIsolated LNs = isolated mediastinal/hilar lymphadenopathy without an intrapulmonary or extrapulmonary mass.
dExtrapulmonary Ca = mediastinal/hilar lymphadenopathy in a known extrapulmonary malignancy, suspected nodal metastases. 
eIntrapulmonary mass = isolated central intrapulmonary mass accessible with EBUS-TBNA.
f Time taken from start of sedation to end of EBUS procedure (includes standard bronchoscopy examination).
EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; FEV
1
, forced expiratory volume in 1 second; DLCO,diffusing capacity of the lung for carbon 
monoxide ; LN, lymph node. 
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advanced nodal stage (N2/3), in elderly patients (45 of 131, 
34.4% versus 31/142, 21.8%; p=0.02; Table 3). The frequency 
of PET-CT before EBUS did not differ according to age cat-
egory (75.4% <70yrs versus 80.9% ≥70yrs, p=0.3). Primary 
lung cancer was diagnosed in 255 patients (93.4%), including 
48 with small-cell and 207 with non–small-cell lung cancer 
(NSCLC; including 17 clinical NSCLC without pathological 
confirmation). A further 17 patients (6.2%) had benign dis-
ease and one patient was confirmed to have a nonprimary lung 
malignancy (Table 3). There was no significant differences 
TABLE 2.  Complications from EBUS-TBNA Stratified According to Performance Status and Indication in <70Yrs and ≥70Yrs Age 
Categories
Measure
Complications
p Value<70 ≥70
Performance status n (%) 0 11/95 (11.6) 1/16 (6.3) 1.0
1 7/115 (6.1) 4/93 (4.3) 0.76
2 4/32 (12.5) 5/77 (6.5) 0.44
3 0/11 (0.0) 0/12 (0.0) 1.0
Indication for EBUS-TBNA n (%) Nodal staging 11/142 (7.7) 6/131 (4.6) 0.32
Advanced stage 1/26 (3.8) 2/25 (8.0) 0.60
Isolated LNsa 8/51 (15.7) 1/19 (5.2) 0.43
Extrapulmonary Cab 1/14 (7.1) 1/8 (12.5) 1.0
Intrapulmonary mass 1/20 (5.0) 0/15 (0.0) 1.0
aIsolated LNs = isolated mediastinal/hilar lymphadenopathy without an intrapulmonary or extrapulmonary mass.
bExtrapulmonary Ca = mediastinal/hilar lymphadenopathy in a known extrapulmonary malignancy, suspected nodal metastases. 
EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; LNs, lymph nodes.
TABLE 3.  Patient Characteristics and Outcomes in Patients Undergoing EBUS-TBNA for Nodal Staging in Suspected or 
Confirmed Primary Lung Cancer Stratified by Age Group
Measure
Age Category (yrs)
p Value<70 ≥70
Final diagnosis  (per patient) n (%) Adenocarcinoma 56 (39.4) 38 (29.0) 0.07
Squamous cell carcinoma 45 (31.7) 36 (27.5) 0.5
NSCLC-NOS 5 (3.5) 7 (5.3) 0.5
Large-cell neuroendocrine 1 (0.7) 2 (1.5) 0.6
Small-cell lung cancer 25 (17.6) 23 (17.6) 1.0
Clinical diagnosis of lung caa 2 (1.4) 15 (11.5) 0.0007
Nonprimary lung cancer 0 (0.0) 1 (0.8) 0.48
Benign pathologyb 8 (5.6) 9 (6.9) 0.8
Total (n=273) 142 131
Pretest radiology/ lymph node 
(mean ±SD)
Lymph node size 1.80 ± 0.8 1.60 ± 0.9 0.09
Nodal SUV 8.44 ± 4.9 7.35 ± 7.2 0.10
LN ultrasound appearances n (%) Heterogeneous 131 (56.0) 96 (47.5) 0.08
Round shape 187 (79.9) 125 (61.9) 0.0001
Distinct margin 126 (53.8) 115 (56.9) 0.56
Coagulation necrosis sign 13 (5.6) 7 (3.5) 1.0
EBUS-TBNA outcome (per lymph 
node) n (%)
Malignant EBUS-TBNA 146 (62.4) 105 (51.9) 0.033
True negative 65 (27.8) 89 (44.1) 0.001
False negative 23 (9.8) 8 (4.0)
Sensitivity % 86.4 92.9 0.12
Negative predictive value % 73.9 91.8 0.001
Diagnostic accuracy % 90.2 96.0 0.02
aClinical diagnosis of lung ca = no histological confirmation but the multidisciplinary team agreed clinical diagnosis of primary lung cancer and definitive management planned.
bBenign pathology = despite radiological concern of primary lung cancer pathological sampling and subsequent follow-up demonstrated benign disease.
Bold type indicates the pivotal results of this study.
NSCLC-NOS, non–small-cell carcinoma “not otherwise specified;” SUV, standardized uptake value (fluorodeoxyglucose activity on PET/CT); PET/CT, positron emission 
tomography/computed tomography.
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between pathological subtypes of lung cancer between the two 
age categories, however, patients aged 70yrs or above were 
more likely to have a clinical diagnosis of lung cancer (not 
confirmed with pathology; p=0.0007; Table 3).
A total of 436 nodes were sampled (234 nodes <70yrs 
and 202 nodes ≥70yrs). The overall prevalence of nodal malig-
nancy was significantly lower in the 70yrs or above category 
(113 of 202, 55.9% versus 169 of 234, 72.2%, p=0.0004). In 
keeping with this, early pathological nodal staging (N0/1), 
compared with advanced nodal staging (N2/3), was more 
frequent in the older cohort (p=0.015; Table 4). Furthermore, 
in patients aged less than 70yrs there were significantly 
more lymph nodes with a rounded shape on ultrasound (a 
feature suggestive of malignancy,9 p=0.0001) and a nonsig-
nificant increase in additional characteristics of malignancy 
in younger patients (heterogeneous echogenicity on ultra-
sound and larger mean short axis size on CT, p=0.08 and 
p=0.09, respectively; Table 3). The frequency of inadequate 
 EBUS-TBNA sampling was almost identical across the two 
age categories (5.1%, 12 of 234, in the <70yrs and 5.0%, 10 
of 202, in the ≥70yrs, p=1.0). The sensitivity (92.9% versus 
86.4%; p=0.12) of EBUS-TBNA in lung cancer nodal stag-
ing was similar between the groups but negative predictive 
value (91.8% versus 73.9%; p=0.001) and diagnostic accu-
racy (96.0% versus 90.2%; p=0.02) was significantly higher 
in the 70yrs or above category (Table 3). The proportion of 
lymph nodes that underwent subsequent surgical sampling 
after negative EBUS-TBNA was significantly higher in the 
less than 70yrs category (40 of 88, 45.5% <70yrs versus 15 of 
97, 15.5% ≥70yrs; p=0.0001).
The vast majority of patients diagnosed with NSCLC 
subsequently went on to have anticancer treatment. Only 
8.2% (17 of 207) of patients in the study received no anti-
cancer treatment and were managed with best supportive 
care. There was no significant difference in the proportion 
of patients receiving best supportive care alone between the 
two age categories. The proportion of patients treated with 
radical radiotherapy was significantly higher in the 70yrs or 
above category (40.8% versus 9.2%; p<0.0001) whereas the 
proportion of patients treated with chemotherapy alone was 
significantly higher in the less than 70yrs category (40.4% 
versus 23.5%; p=0.011). Surgical resection occurred more 
frequently in the less than 70yrs age group, but this difference 
did not reach statistical significance (27.5% versus 17.3%; 
p=0.097; Table 4).
Efficacy of EBUS-TBNA in  Advanced-
Stage Primary Lung Cancer (Only 
Pathological Confirmation Required)
Overall 51 patients (26 patients <70yrs and 25 patients 
≥70yrs) underwent EBUS-TBNA in whom the pretest radiol-
ogy was consistent with advanced-stage primary lung cancer, 
unsuitable for radical therapy, such that formal nodal staging 
was not required and pathological confirmation was the aim of 
the procedure. In 25 of 26 patients less than 70yrs, pathological 
confirmation was achieved (14 adenocarcinoma, 5 squamous 
cell carcinoma, 3 small-cell carcinoma and 2 NSCLC–not 
otherwise specified [NOS]) but one patient required a further 
procedure after a nondiagnostic EBUS-TBNA (a bone biopsy 
that confirmed metastatic melanoma). In all 25 patients aged 
70yrs or above pathological confirmation was achieved (10 
adenocarcinoma, 7 squamous cell carcinoma, 5 small-cell car-
cinoma, 1 NSCLC-NOS, 1 metastatic breast carcinoma, and 1 
metastatic pancreatic carcinoma).
TABLE 4.  Comparison of CT Nodal Staging in All Patients Referred for Nodal Staging with EBUS-TBNA and Pathological Nodal 
Staging Plus Treatment Outcome in Patients Subsequently Diagnosed with Non–Small-Cell Lung Cancer Stratified by Age 
Category
Measure
Age Category (yrs)
p Value<70 ≥70
CT nodal staging n (%)  
n=273 patients
N0 17 (12.0) 20 (15.3) 0.48
N1 14 (9.9) 25 (19.1) 0.037
N2 85 (59.8) 68 (51.9) 0.22
N3 26 (18.3) 18 (13.7) 0.33
Total 142 131
Pathological staging in NSCLC n (%) 
n=207 patients
N0 23 (21.1) 34 (34.7) 0.03
N1 10 (9.2) 12 (12.2) 0.5
N2 51 (46.8) 38 (38.8) 0.26
N3 25 (22.9) 14 (14.3) 0.15
Total 109 98
Treatment outcome in NSCLC n (%) 
n=207 patients
Surgical resection 30 (27.5) 17 (17.3) 0.097
Radical radiotherapy 10 (9.2) 40 (40.8) 0.0001
Concurrent chemoradiotherapy 18 (16.5) 9 (9.2) 0.15
Chemotherapy 44 (40.4) 23 (23.5) 0.011
Best supportive care 7 (6.4) 9 (9.2) 0.6
Total 109 98 —
CT, computed tomography; EBUS-TBNA; endobronchial ultrasound-guided transbronchial needle aspiration; NSCLC, non–small-cell carcinoma.
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Pathological Subtyping and Molecular Testing
Overall, 244 patients were diagnosed with NSCLC 
using EBUS-TBNA. The NSCLC-NOS rate was low, 5.9% 
(8 of 136) of patients less than 70yrs compared with 7.4% 
(8 of 108) of patients 70yrs or above (p=0.63). EBUS-TBNA 
provided adequate tissue for epidermal growth factor receptor 
(EGFR) mutation testing in 94.5% (n=52 of 55 aged <70yrs 
and n=29 of 30 aged ≥70yrs; p=1.0) of patients.
DISCUSSION
The complication rate of EBUS-TBNA in this study was 
low and comparable with that of previous reports.13–15 There 
was no difference in overall complication rate when analyzed 
according to age, despite significantly lower performance 
status in the 70yrs or above cohort and one in three patients 
being aged 80yrs or older. Indeed tolerance of the procedure, 
as measured by the requirement for early termination, was sig-
nificantly better in the older-age cohort.
The efficacy of EBUS-TBNA was assessed in patients 
undergoing nodal staging with confirmed or suspected lung can-
cer. No difference in sensitivity was seen according to age thresh-
old, however, negative predictive value and diagnostic accuracy 
were significantly higher in those aged 70yrs or above. This was 
a surprise finding and most likely reflects a higher rate of false-
negative sampling in the younger cohort. A possible explana-
tion is the higher rate of surgical sampling (via mediastinoscopy 
or lymph node dissection during resection) in the younger-age 
group, which may increase the probability of a false-negative 
sample being detected. Older patients had lower rates of repeat 
invasive sampling and as a consequence a higher reliance on 
clinical–radiological follow-up to define the final lymph node 
diagnosis. This may not be as reliable as surgical sampling. In 
addition, reduced procedure tolerance in some younger patients 
may have resulted in less-effective sampling, although the fre-
quency of sample inadequacy was the same for both age cohorts. 
Regardless of the differences between the age categories, it is clear 
nodal staging can be performed effectively in elderly patients.
The analysis of EBUS-TBNA efficacy for staging was 
performed on patients with pathologically confirmed NSCLC 
requiring nodal staging to define treatment and also patients 
with a high radiological suspicion of NSCLC where nodal sam-
pling could both define nodal stage and provide pathological 
confirmation. This second group of patients comprised those 
who were subsequently found to have a benign pathology (e.g., 
an inflammatory lung lesion with reactive lymphadenopathy) 
and those with small-cell lung cancer. These patients were kept 
in the analysis, rather than restricting it to those with NSCLC 
only, to ensure that the performance of EBUS-TBNA was 
assessed in a real-life cohort referred for nodal staging. There 
was no difference in the prevalence of benign disease and small-
cell lung cancer in the two age categories and this therefore 
should not bias the analysis. Patients in whom EBUS-TBNA 
was performed because of isolated mediastinal lymphadenopa-
thy, lymphadenopathy in the context of an extrapulmonary can-
cer or to sample an intrapulmonary mass, and in whom NSCLC 
was subsequently diagnosed, were not included in the staging 
analysis as our approach to formal staging during EBUS with 
systematic mediastinal examination was not performed.
The overall prevalence of nodal malignancy was sig-
nificantly lower in the 70yrs or above category and patients 
aged less than 70yrs were referred for EBUS-TBNA with sig-
nificantly higher nodal staging based on pre-EBUS CT (N2/3 
versus N0/1). This could reflect a selection bias in our study 
population. It is possible that physicians referring elderly 
patients for EBUS-TBNA tend to refer those with early-stage 
disease, N0/1, rather than those with a suspicion of N2/3 dis-
ease on CT. Worryingly, this could reflect a willingness to 
attempt pathological confirmation of suspected N2/3 disease 
in younger patients but a reliance on noninvasive staging in 
elderly patients with the same radiological findings. This is 
in keeping with the final pathological nodal staging where a 
significantly higher proportion of patients aged 70yrs or above 
were N0. This difference in population characteristics may 
explain why treatments given to patients differed according 
to age. Older patients, who were more likely to be staged as 
N0 but were of poorer performance status, were more likely to 
receive radical radiotherapy and less likely to have a surgical 
resection (although this did not reach statistical significance). 
Younger patients were also more likely to be treated with che-
motherapy, reflecting more advanced disease.
The overall NSCLC-NOS rate of 6.6% was lower than 
previously reported values of 20% to 23% from EBUS-TBNA 
lymph node sampling16,17 and is a reflection of the appropriate 
handling of tissue samples and the use of immunohistochemis-
try. In addition, the advent of targeted therapies for tumors with 
specific DNA mutations, for example, EGFR mutation, has 
emphasized the importance of accurate histological typing and 
sufficient tissue for molecular testing. EGFR mutation analysis 
was successfully achieved in 96.5% of EBUS-TBNA samples 
and comparable with that in a recent large multicenter study.17
In conclusion, this large prospective study of 
 EBUS-TBNA has specifically addressed patient safety and 
procedural outcomes in elderly patients (defined as ≥70yrs to 
correspond to the median age of lung cancer diagnosis and 
a common cutoff point in clinical trials).18 EBUS-TBNA is 
safe and highly effective in achieving accurate nodal stag-
ing, pathological confirmation, and morphological subtyping, 
while allowing sufficient tissue for molecular testing and can 
therefore be safely offered to elderly patients with suspected 
lung cancer as part of an integrated management program and 
will facilitate access to the most appropriate cancer treatment.
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